Austin Men's Health Clinic Chain Agrees to Up to $600,000 in Controlled Substances Act Settlement

A men's health clinic operator in central Texas has agreed to pay civil penalties to resolve federal allegations that it mishandled controlled substances, including how prescriptions were signed and transmitted. The case is a civil enforcement action under the Controlled Substances Act, and it turns on recordkeeping and prescribing practices rather than any criminal charge. It is a useful window into how federal regulators scrutinize the controlled substance side of the men's health and telehealth prescribing business.

What the government announced

According to the U.S. Attorney's Office for the Western District of Texas, Total MD Physicians Group, P.L.L.C., doing business as Total Men's Primary Care, and Dr. Mason Jones agreed to a consent judgment requiring them to pay up to $600,000 in civil penalties for alleged violations of the Controlled Substances Act (21 U.S.C. Sections 801 and following). The office announced the resolution on July 24, 2026. The Drug Enforcement Administration's San Antonio Division investigated the matter.

The announcement describes Dr. Jones as a physician registered with the DEA to handle controlled substances at several Total Men's Primary Care clinics in the Austin area. Any DEA registrant that prescribes, dispenses, or otherwise handles controlled substances takes on specific federal obligations, and this case concerns whether those obligations were met.

The settlement terms

The consent judgment sets the potential penalty at up to $600,000. Under the terms described by the government, Total Men's Primary Care and Dr. Jones can satisfy their obligation by paying $300,000 within 12 months. A consent judgment is a negotiated resolution entered by a court, and here it resolves the government's civil claims without a trial.

Importantly, the government's statement makes clear that the claims resolved by the settlement are allegations only and that there has been no determination of liability. A civil settlement of this kind is not a criminal conviction and does not, by itself, establish that the alleged conduct occurred.

What was alleged

The government alleged two categories of conduct. First, it alleged a failure to comply with the recordkeeping requirements that apply to DEA registrants who handle controlled substances. Second, and more relevant to telehealth, it alleged the electronic signing and transmitting of prescriptions for a Schedule II controlled substance without a doctor-patient relationship. The public announcement did not name the specific Schedule II substance.

The allegations trace back to 2023, when the DEA conducted onsite inspections of three of the company's clinics in the Austin area, in Austin, Bee Cave, and Cedar Park. Onsite inspections of a registrant's records and practices are a routine DEA tool for checking controlled substance compliance.

What officials said

In the announcement, U.S. Attorney Justin R. Simmons said, "When medical providers violate patient trust and federal law, my Office will hold them accountable through whatever means available." DEA Special Agent in Charge Miguel Madrigal said, "Reckless and unlawful prescribing practices endanger public health, fuel prescription drug misuse, and undermine the integrity of the medical profession."

Why this matters for telehealth and men's health clinics

The allegation that stands out for the telehealth audience is the electronic signing and transmitting of Schedule II prescriptions without a doctor-patient relationship. Schedule II drugs are the most tightly controlled category that can still be prescribed, and federal law generally requires that a controlled substance prescription be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice. Electronic prescribing is now standard, but the electronic signature does not remove the underlying requirement for a valid clinical relationship and proper records behind each prescription.

Men's health has become a fast growing telehealth vertical, and many clinics and online platforms in the category prescribe medications that touch controlled substance rules. This case is a reminder that regulators are examining the mechanics of how those prescriptions are generated, signed, and documented, not just the marketing around them.

What compliant controlled substance prescribing generally requires

This is general information, not legal or medical advice. Under federal controlled substance rules, DEA-registered prescribers are generally expected to do the following:

• Issue controlled substance prescriptions only for a legitimate medical purpose, based on a genuine evaluation of the patient rather than a signature detached from any clinical encounter.
• Maintain complete and accurate records of controlled substances handled, dispensed, or prescribed, and make those records available for DEA inspection.
• Follow the heightened requirements that apply specifically to Schedule II substances, which are the most restricted drugs a clinician can still prescribe.
• Ensure that electronic prescribing systems are used in a way that preserves, rather than bypasses, the requirement for a valid prescription.

Patients who use online or in-person men's health services and have questions about a specific prescription should raise them with a licensed clinician or pharmacist. The primary sources below are the authoritative record of what the government actually alleged and agreed to.

The broader enforcement picture

Civil penalty settlements under the Controlled Substances Act have become a common enforcement tool, allowing the government to resolve alleged recordkeeping and prescribing lapses without a criminal case. For the telehealth and men's health industry, the through line is that the controlled substance workflow, from the clinical relationship to the records that document it, is squarely within federal regulators' focus. The specifics of any one settlement are limited to that matter, and this resolution reflects allegations that were not tested at trial.